By combining the use of drug-carrying nanoparticles with an organ-preserving machine, researchers have developed a procedure that could help improve long-term outcomes for transplant recipients.

A technology known as ex vivo normothermic machine perfusion (NMP) has emerged in recent years as a means of keeping a donor organ “alive” outside the body before implantation. It has also helped increase the number of organs suitable for transplant. Researchers are working to expand the technology’s rehabilitation abilities with a nanoparticle-based drug-delivery system that can deliver a variety of treatments directly to critical targets in a human kidney while it is still in the device.

To target the cells, researchers coated nanoparticles with an antibody that targets CD31, a protein abundant in the endothelium. These particles were injected into the perfusion device while its fluid was passing through a donor kidney for periods of four to six hours.


Medical Design Briefs Magazine

This article first appeared in the November, 2017 issue of Medical Design Briefs Magazine.

Read more articles from this issue here.

Read more articles from the archives here.